


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-46 (Deleted)

47. (New) A succinate salt or a malonate salt of the compound of formula (I)



48. (New) The succinate salt of claim 47, wherein the succinate salt is the hydrogen succinate salt.

49. (New) The hydrogen succinate salt of claim 48, wherein the hydrogen succinate salt is a crystalline hydrogen succinate salt.

50. (New) The crystalline hydrogen succinate salt of claim 49, wherein the crystal form is alpha.

51. (New) The crystalline hydrogen succinate salt of claim 49, wherein the crystal form is characterized by an X-Ray powder diffractogram as shown in Figure 1.

52. (New) The crystalline hydrogen succinate salt of claim 51, wherein the X-Ray powder diffractogram was obtained using CuK_{α1} radiation ($\lambda=1.5406 \text{ \AA}$) showing peaks at the following 2θ-angles: 9.36; 10.23; 11.81; 13.45; 16.21; 16.57; 17.49; 18.89; 19.20; 19.63; 20.01; 20.30; 21.15; 21.53; 21.93; 22.34; 24.37; 25.34; 27.27; 29.65.
53. (New) The crystalline hydrogen succinate salt of claim 49, wherein the crystal form is characterized by having a DSC trace showing an endotherm with onset about 139-141°C.
54. (New) The malonate salt of claim 47, wherein the malonate salt is the hydrogen malonate salt.
55. (New) The hydrogen malonate salt of claim 54, wherein the hydrogen malonate salt is a crystalline hydrogen malonate salt.
56. (New) The crystalline hydrogen malonate salt of claim 55, wherein the crystal form is characterized by an X-Ray powder diffractogram as shown in Figure 3.
57. (New) The crystalline hydrogen malonate salt of claim 56, wherein the X-Ray powder diffractogram was obtained using CuK_{α1} radiation ($\lambda=1.5406 \text{ \AA}$) showing peaks at the following 2θ-angles: 2θ-angles: 8.3; 10.6; 11.5; 12.8; 14.2; 14.5; 14.7; 15.8; 16.5; 17.4; 17.6; 18.0; 18.6; 19.2; 21.2; 22.0; 22.9; 23.7; 24.7; 28.8.
58. (New) A pharmaceutical composition comprising the salt of claim 47 and at least one pharmaceutically acceptable carrier, filler or diluent.
59. (New) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the salt of claim 47, wherein the disease or disorder is selected from the group consisting of a disorder

exhibiting psychotic symptoms, a psychotic disorder, an anxiety disorder, an affective disorder, depression, a sleep disturbance, migraine, neuroleptic-induced parkinsonism, and an abuse disorder.

60. (New) The method of claim 59, wherein the abuse disorder is selected from the group consisting of cocaine abuse, nicotine abuse and alcohol abuse.
61. (New) The method of claim 59, wherein the disease or disorder is schizophrenia or a psychotic disorder.
62. (New) The method of claim 61, wherein the schizophrenia comprises positive symptoms, negative symptoms and/or depressive symptoms.
63. (New) A method of treating a subject suffering from a disease or disorder comprising administering to the subject a therapeutically effective amount of the salt of claim 47, wherein the disease or disorder is selected from the group consisting of Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder and mania in bipolar disorder.